CN109645489A - A kind of probiotic composition and its application for inhibiting helicobactor pylori activity - Google Patents
A kind of probiotic composition and its application for inhibiting helicobactor pylori activity Download PDFInfo
- Publication number
- CN109645489A CN109645489A CN201811510562.5A CN201811510562A CN109645489A CN 109645489 A CN109645489 A CN 109645489A CN 201811510562 A CN201811510562 A CN 201811510562A CN 109645489 A CN109645489 A CN 109645489A
- Authority
- CN
- China
- Prior art keywords
- probiotic composition
- parts
- helicobacter pylori
- powder
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 239000006041 probiotic Substances 0.000 title claims abstract description 45
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 45
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 40
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 7
- 230000000694 effects Effects 0.000 title abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 33
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 27
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 27
- 235000013312 flour Nutrition 0.000 claims abstract description 19
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 17
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 17
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 17
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 17
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 17
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 15
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 15
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 15
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- CAXNYFPECZCGFK-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylacetonitrile Chemical compound C=1C=CC=NC=1C(C#N)C1=CC=CC=C1 CAXNYFPECZCGFK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000004879 dioscorea Nutrition 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 5
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 4
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 4
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 4
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 abstract description 9
- 208000024798 heartburn Diseases 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 9
- 206010028813 Nausea Diseases 0.000 abstract description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 description 14
- 206010019375 Helicobacter infections Diseases 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000003825 pressing Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010006326 Breath odour Diseases 0.000 description 3
- 208000032139 Halitosis Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 description 2
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of probiotic composition and application thereof for inhibiting helicobactor pylori activity, the probiotic composition is made of the raw material of following weight proportion: 0.1-8 parts of lactobacillus acidophilus, 0.1-8 parts of Lactobacillus rhamnosus, 0.1-2 parts of soyabean protein powder, 1-20 parts of yam flour, 10-30 parts of oligofructose, 10-30 parts of galactooligosaccharide, 1-20 parts of apple powder, 1-20 parts of maltodextrin.The present invention provides that a kind of effect is prominent, prescription is simple, a kind of taste good probiotic composition, for preventing and treating the infection of helicobacter pylori, and alleviating the symptoms such as nauseous, heartburn being induced by it.
Description
(1) technical field
The present invention relates to a kind of probiotic compositions and application thereof for inhibiting helicobacter pylori activity, belong to function food
Product field.
(2) background technique
Helicobacter pylori (Helicobacter pylori) is a kind of Gram-negative bacteria, survives in stomach and 12 fingers
In each region of intestines.The chronic inflammation that it can cause stomach lining slight, even lead to gastric and duodenal ulcer and gastric cancer.Pylorus
Helicobacter disease belongs to micro- anaerobism, the bacterium very harsh to growth conditions requirement.Nineteen eighty-three suffers from from chronic active gastritis for the first time
It is separated successfully in the Gastric mucosa biopsy tissue of person, is the currently known only microbe species that can be survived in people's stomach.
Under normal circumstances, stomach wall have a series of perfect self-protective mechanisms (secreting function of gastric acid, pepsin, no
The protective effect of dissolubility and soluble mucous layer, regular movement etc.), invading for the 1100 kinds of microorganisms orally entered can be resisted
It attacks.Since after gastric epithelial cell surface has found helicobacter pylori, just recognize helicobacter pylori almost can
Break through unique arch-criminal of this natural barrier.
Helicobacter pylori can cause chronic gastritis, and the course of disease is more slow, but be easy recurrent exerbation.Helicobacter pylori
The symptom of dye is mainly sour regurgitation, heartburn and stomachache, halitosis.This is mainly due to helicobacter pyloris to induce gastrin madness point
It secretes, and it is heartburn to turn sour, and the patient with gastric ulcer, helicobacter pylori are even more the hair for causing cardinal symptom stomachache
Raw, one of most direct germ of halitosis is exactly helicobacter pylori.After helicobacter pylori infections, serious conditions person occurs for stomach,
Just carry out the anti-infective therapy for this pathogenic bacteria.Because helicobacter pylori is difficult to eradicate, a variety of medicines are generally chosen in treatment
Object use in conjunction is also difficult to ensure from now on even if germ is cleaned up after current treatment not by subinfection again.
Current a variety of antibacterials use in conjunction are still the main method for treating helicobacter pylori.With proton pump inhibitor
(PPI) triple therapy for combining two kinds of antibacterials composition is the standard scheme of generally acknowledged elimination helicobacter pylori.But because of antibacterial
Adverse drug reaction is larger, and compliance is poor, and resistant rate is higher and higher, and making elimination, the effect is unsatisfactory.With microecology
The application with Tiny ecosystem therapy is risen, provides new approaches for the treatment of helicobacter pylori.In terms of to anti-helicobacter pylori, no
Between the factors such as same strain, different strains, viable count, strain/bacterial strain ratio, there are significant difference, so screening optimum strain,
Collocation optimal proportion is crucial.
The probiotics preparation of existing some treatment helicobacter pylori infections, is the probiotics preparation of drug series mostly,
And or be single strain, such as beneficial monarch health (lactobacillus acidophilus 5 × 106CFU/ piece), compound lactobacillus acidophilus piece (0.25 ×
107CFU/ piece)；It is inactivated bacteria, such as lacteol fort (1 × 1010CFU/ bags, inactivation)；It is simple Bifidobacterium combination,
Such as Infantile diarrhea (0.5 × 107CFU/ piece).Furthermore existing dosage form viable count is in reduced levels mostly, and effect is limited.
(3) summary of the invention
Object of the present invention is to the deficiencies for the market demand and existing product, pass through screening dominant strain, science adjustment bacterium
Strain ratio provides the best viable count for meeting effect, while the Gastro- that arranges in pairs or groupsSoyabean protein powder, yam flour and prebiotic
Member etc., to provide, a kind of effect is prominent, prescription is simple, a kind of taste good probiotic composition, for preventing and treating pylorus spiral shell
The infection of bacillus, and alleviate the symptoms such as nauseous, heartburn being induced by it.
The technical solution adopted by the present invention is that:
The present invention provides a kind of for inhibiting the active probiotic composition of helicobacter pylori, the probiotic composition
It is made of the raw material of following weight proportion:
Further, the preferably described probiotic composition is made of the raw material of following weight proportion:
Further, the probiotic composition is made of the raw material of following weight proportion:
Further, the lactobacillus acidophilus specification is 6 × 1010CFU/g, more preferably purchased from Canadian Lallemand USA Inc., bacterial strain
Number be R052；The Lactobacillus rhamnosus specification is 1 × 1011CFU/g, more preferably purchased from Canadian Lallemand USA Inc., bacterial strain number is
R343.The soyabean protein powder is Gastro-Soyabean protein powder (is purchased from Guangzhou Neng Jing Bioisystech Co., Ltd), is to adopt
It is raw material with Non-transgenic soybean, is formed using Lactobacillus delbrueckii category subspecies bulgaricus Rosell-0187 as strain fermentation；It is described
Yam flour is Chinese yam medicinal powder (regulation for meeting DBS41/009)；The oligofructose molecular weight is that 504-828 (meets GB/T
23528 regulation)；The galactooligosaccharide molecular weight is that 800-2000 (meets the Ministry of Public Health and announces No. 20 rule in 2008
It is fixed)；The apple powder meets the regulation of GB/T 29602；The maltodextrin meets the regulation of GB/T 20884.
Further, probiotic composition of the present invention is prepared as follows: respectively by yam flour, oligofructose, low
Poly- galactolipin, apple powder, maltodextrin cross 60 meshes, then mix by formula ratio, then respectively by the Gastro- of formula ratioSoyabean protein powder, lactobacillus acidophilus, Lactobacillus rhamnosus are added in such a way that equivalent is progressively increased, and mix, and obtain probiotics
Composition.
The present invention also provides a kind of probiotic compositions of stating in the functional food that preparation inhibits helicobacter pylori
Using the microbial symptom of H. pylori can be alleviated or be eradicated to the functional food, and the symptom includes sour regurgitation, burns
The heart, stomachache, halitosis etc..
The present invention is compared to existing product formula and technology in the market, and it is excellent to have the following beneficial effects: that the present invention selects
Gesture bacterial strain, provides the best viable count for meeting effect at science adjustment bacterial strain ratio；Gastro- is added simultaneouslySoybean protein
Powder, can nausea caused by rapid recovery helicobacter pylori infections, the symptoms such as heartburn；Prebiotics in formula are (oligofructose, oligomeric
Galactolipin), the proliferation of beneficial bacterium can be stimulated, and probiotics can be promoted in the field planting of gastrointestinal tract；And Chinese yam then has strengthening spleen and nourishing stomach
Effect.Entirely formula collocation is reasonable, short-acting and long-acting combination, for inhibiting or removing helicobacter pylori, and alleviation by it
The caused symptoms such as nauseous, heartburn have significant effect.In addition, preparation method of the present invention is simple, the technological process of production is few, cost
It is lower, drink conveniently, practicability with higher, be conducive to large-scale production.
(4) specific embodiment
The present invention is described further combined with specific embodiments below, but protection scope of the present invention is not limited in
This:
Lactobacillus acidophilus (Lactobacillus acidophilus, purchased from Canadian Raman public affairs in the embodiment of the present invention
Department, strain number R052, activity 6 × 1010CFU/g；Lactobacillus rhamnosus (Lactobacillus rhamnosus) is purchased from and adds
It puts on airs Lallemand USA Inc., strain number R343, activity 1 × 1011CFU/g；Gastro-Soyabean protein powder is to turn base using non-
Because soybean is raw material, formed using Lactobacillus delbrueckii category subspecies bulgaricus Rosell-0187 as strain fermentation, it can be beautiful purchased from Guangzhou
Bioisystech Co., Ltd.The yam flour is Chinese yam medicinal powder (regulation for meeting DBS41/009).The oligofructose molecular weight
For 504-828；The galactooligosaccharide molecular weight is 800-2000；The apple powder meets the regulation of GB/T 29602；It is described
Maltodextrin meets the regulation of GB/T 20884.
Lactobacillus acidophilus NCFM, activity 6 × 1010CFU/g is purchased from Danisco (China) Co., Ltd；Rhamnose cream bar
Bacterium R0011, activity 6 × 1010CFU/g is purchased from Danisco (China) Co., Ltd.
Embodiment 1:
1, it is formulated
A kind of probiotic composition with inhibition helicobacter pylori effect, by being made with the raw material of weight proportion:
2, process flow
Yam flour, oligofructose, galactooligosaccharide, apple powder, maltodextrin are crossed into 60 meshes respectively.Formula ratio is pressed again,
It by yam flour 1g, oligofructose 10g, galactooligosaccharide 10g, apple powder 1g, maltodextrin 1g, mixes, then respectively will
Gastro-Soyabean protein powder 0.1g, lactobacillus acidophilus R052 bacterium powder 0.1g, Lactobacillus rhamnosus R343 bacterium powder 0.1g are pressed
It is added, mixes according to the mode that equivalent is progressively increased, obtain probiotic composition, finally dispense.
Embodiment 2:
1, it is formulated
A kind of probiotic composition with inhibition helicobacter pylori effect, is prepared from the following raw materials in parts by weight:
2, process flow
Yam flour, oligofructose, galactooligosaccharide, apple powder, maltodextrin are crossed into 60 meshes respectively.Pressing formula ratio again will
Yam flour 10g, oligofructose 20g, galactooligosaccharide 20g, apple powder 10g, maltodextrin 10g are mixed, and then respectively will
Gastro-Soyabean protein powder 1g, lactobacillus acidophilus R052 bacterium powder 4g, Lactobacillus rhamnosus R343 bacterium powder 4g are according to equivalent
The mode progressively increased is added, and mixes, and obtains probiotic composition, finally dispenses.
Embodiment 3:
1, it is formulated
A kind of probiotic composition with inhibition helicobacter pylori effect, is prepared from the following raw materials in parts by weight:
2, process flow
Yam flour, oligofructose, galactooligosaccharide, apple powder, maltodextrin are crossed into 60 meshes respectively.Pressing formula ratio again will
Yam flour 20g, oligofructose 30g, galactooligosaccharide 30g, apple powder 20g, maltodextrin 20g are mixed, and then respectively will
Gastro-Soyabean protein powder 2g, lactobacillus acidophilus R052 bacterium powder 8g, 8 parts of powder of Lactobacillus rhamnosus R343 bacterium according to equivalent
The mode progressively increased is added, and mixes, and obtains probiotic composition.Finally dispense.
Comparative example 1
1, it is formulated
Probiotic composition is prepared from the following raw materials in parts by weight:
2, process flow
Yam flour, oligofructose, galactooligosaccharide, apple powder, maltodextrin are crossed into 60 meshes respectively.Pressing formula ratio again will
Yam flour 10g, oligofructose 20g, galactooligosaccharide 20g, apple powder 10g, maltodextrin 10g are mixed, then by Gastro-Soyabean protein powder 2g is added in such a way that equivalent is progressively increased, and mixes, and obtains probiotic composition, finally dispenses.
Comparative example 2
1, it is formulated
Probiotic composition is prepared from the following raw materials in parts by weight:
2, process flow
Yam flour, oligofructose, galactooligosaccharide, apple powder, maltodextrin are crossed into 60 meshes respectively.Pressing formula ratio again will
Yam flour 10g, oligofructose 20g, galactooligosaccharide 20g, apple powder 10g, maltodextrin 10g are mixed, then respectively by acidophilus
Lactobacillus R052 powder 4g, Lactobacillus rhamnosus R343 bacterium powder 4g, are added in such a way that equivalent is progressively increased, and mix, and obtain probiotics
Composition finally dispenses.
Comparative example 3
1, it is formulated
Probiotic composition is prepared from the following raw materials in parts by weight:
2, process flow
Yam flour, oligofructose, galactooligosaccharide, apple powder, maltodextrin are crossed into 60 meshes respectively.Pressing formula ratio again will
Yam flour 10g, oligofructose 20g, galactooligosaccharide 20g, apple powder 10g, maltodextrin 10g are mixed, and then respectively will
Gastro-Soyabean protein powder 1g, (specification is the same as lactobacillus acidophilus R052) 4g, Lactobacillus rhamnosus for lactobacillus acidophilus NCFM powder
(specification is added in such a way that equivalent is progressively increased R0011 bacterium powder with Lactobacillus rhamnosus R343) 4g, mixes, and obtains probiotic group
Object is closed, is finally dispensed.
Embodiment 4
1, test method
HP positive patient 140,7 groups are randomly divided into, each 20, two groups in the state of an illness, primary disease, age, gender, disease
Journey, haemodialysis scheme etc. no significant difference, all have comparativity.1-6 group is test group, and the 7th group is control
Group.
Control group patient gives conventional triple therapy, and taking orally Omeprazole, (Beijing Pacific Ocean pharmaceutcal corporation, Ltd, traditional Chinese medicines are quasi-
Word H1999014) 0.6-1mg/ (kgd), clarithromycin (Beijing Jiade pharmaceutical Co. Ltd, national drug standard H20000136)
15-20mg/ (kgd), Amoxicillin (Zhuhai United Laboratories Ltd, national drug standard H44024970) 50mg/
(kgd), 2 times/d, course for the treatment of 14d.1-6 group gives the group in embodiment and comparative example on the basis of conventional triple therapy respectively
Conjunction object, 3g/ times, 2 times/d, course for the treatment of 14d.
Each group is gone after the course for the treatment of terminates 4 weeks again respectively14C urea breath test, detection helicobacter pylori infections whether by
Eradicate (HP is negative).
2, statistical method
Measurement data withIt indicating, paired t-test is relatively used in group, and comparison among groups use one-way analysis of variance,
Enumeration data uses χ2It examines.
3, helicobacter pylori eradication situation
Different samples corresponding to reference examples, embodiment and comparative example, to the effect of helicobacter pylori eradicating rate, such as table 1
It is shown.
The different samples of table 1 to the effect of helicobacter pylori eradicating rate (n=20,)
Note: p < 0.05 * is significant difference, p < 0.01 * *, compared with the control group for difference and significantly compared with the control.
As can be seen from Table 1, in terms of helicobacter pylori eradicating rate, embodiment will be apparently higher than comparative example and reference examples, root
It is the corresponding composition of embodiment 2 except rate is highest, up to 95%, control is minimum, is 45%.3 groups corresponding to embodiment
(1-3 group), adverse reaction rate is zero；Control group adverse reaction rate highest, up to 65%；Comparative example 15%-25% is differed.
4, remission status
Different samples corresponding to reference examples, embodiment and comparative example, to remission caused by helicobacter pylori infections
Effect, as shown in table 2.
The different samples of table 2 to remission effect caused by helicobacter pylori infections (n=20,)
Note: p < 0.05 * is significant difference, p < 0.01 * *, compared with the control group for difference and significantly compared with the control.
As can be seen from Table 2, in terms of alleviating nausea caused by helicobacter pylori infections, heartburn symptom, embodiment is compared
Ratio effect becomes apparent from, wherein test group nausea ratio, the heartburn ratio of taking 2 sample of embodiment are all 0.Although and comparative example
There is certain effect, but there are larger gaps compared with embodiment.
5, conclusion
Above data shows that the factors such as strain specificity, number of viable, bacterial strain collocation and formula rate are assisting in the treatment of
It is made a significant impact during helicobacter pylori infections.Probiotic composition according to the present invention is controlled in conventional triple therapy
In the treatment for treating helicobacter pylori infections, eradication rate can be significantly improved, and the diseases such as nauseous, heartburn caused by infection can be significantly improved
Shape.
Claims (10)
1. one kind is for inhibiting the active probiotic composition of helicobacter pylori, it is characterised in that the probiotic composition by
The raw material of following weight proportion is made:
2. probiotic composition as described in claim 1, it is characterised in that the probiotic composition is by following weight proportion
Raw material be made:
3. probiotic composition as described in claim 1, it is characterised in that the probiotic composition is by following weight proportion
Raw material be made:
4. the probiotic composition as described in one of claim 1-3, it is characterised in that the vigor of the lactobacillus acidophilus be 6 ×
1010CFU/g, the vigor of Lactobacillus rhamnosus are 1 × 1011CFU/g。
5. probiotic composition as claimed in claim 4, it is characterised in that the lactobacillus acidophilus be lactobacillus acidophilus R052,
The Lactobacillus rhamnosus is Lactobacillus rhamnosus R343.
6. the probiotic composition as described in one of claim 1-3, it is characterised in that the soyabean protein powder is Gastro- Soyabean protein powder.
7. the probiotic composition as described in one of claim 1-3, it is characterised in that the yam flour is Chinese yam medicinal powder.
8. the probiotic composition as described in one of claim 1-3, it is characterised in that the oligofructose molecular weight is 504-
828, the galactooligosaccharide molecular weight is 800-2000.
9. probiotic composition as described in claim 1, it is characterised in that the probiotic composition is prepared as follows:
Yam flour, oligofructose, galactooligosaccharide, apple powder, maltodextrin are crossed into 60 meshes respectively, it is then even by formula ratio, then
Respectively by the Gastro- of formula ratioThe side that soyabean protein powder, lactobacillus acidophilus, Lactobacillus rhamnosus are progressively increased according to equivalent
Formula is added, and mixes, and obtains probiotic composition.
10. probiotic composition described in a kind of claim 1 inhibits the application in the active food of helicobacter pylori in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811510562.5A CN109645489A (en) | 2018-12-11 | 2018-12-11 | A kind of probiotic composition and its application for inhibiting helicobactor pylori activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811510562.5A CN109645489A (en) | 2018-12-11 | 2018-12-11 | A kind of probiotic composition and its application for inhibiting helicobactor pylori activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109645489A true CN109645489A (en) | 2019-04-19 |
Family
ID=66114062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811510562.5A Pending CN109645489A (en) | 2018-12-11 | 2018-12-11 | A kind of probiotic composition and its application for inhibiting helicobactor pylori activity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109645489A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110638050A (en) * | 2019-10-08 | 2020-01-03 | 大连山海物华科技开发有限公司 | Health food for resisting helicobacter pylori, invigorating spleen and removing dampness and preparation thereof |
| CN111671079A (en) * | 2020-05-13 | 2020-09-18 | 优益生活(北京)健康科技有限公司 | Composite probiotic powder composition and preparation method thereof |
| CN113287754A (en) * | 2021-05-26 | 2021-08-24 | 北京东方红航天生物技术股份有限公司 | Food composition for resisting helicobacter pylori |
| CN114306395A (en) * | 2021-12-29 | 2022-04-12 | 湖南营养树生物科技有限公司 | Probiotic composition capable of releasing ORNs and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006188439A (en) * | 2004-12-28 | 2006-07-20 | Showa Sangyo Co Ltd | Helicobacter pylori adhesion-inhibiting composition, and food and drink |
| CN106343022A (en) * | 2016-08-19 | 2017-01-25 | 盛昌达国际贸易（天津）有限公司 | Health-care yoghurt with helicobacter pylori inhibiting effect and production method of health-care yoghurt |
| CN106491657A (en) * | 2016-10-25 | 2017-03-15 | 广西泰和制药有限公司 | A kind of health food for strengthening regulating intestinal canal flora function and preparation method thereof |
| CN106901344A (en) * | 2017-03-16 | 2017-06-30 | 北京知蜂堂健康科技股份有限公司 | A kind of composition for alleviating stomachache stomachache and its application |
| CN107149151A (en) * | 2017-06-05 | 2017-09-12 | 上海真合生物技术有限公司 | The probiotic composition of helicobacter pylori resistant |
| CN107996936A (en) * | 2017-12-15 | 2018-05-08 | 徐州统食品工业有限公司 | A kind of solid beverage for improving stomach health problem |
| CN108904546A (en) * | 2018-07-10 | 2018-11-30 | 山东腾贵医药有限公司 | A kind of pair of helicobacter pylori has inhibition, the probiotic combinations preparation of killing effect and preparation method thereof |
-
2018
- 2018-12-11 CN CN201811510562.5A patent/CN109645489A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006188439A (en) * | 2004-12-28 | 2006-07-20 | Showa Sangyo Co Ltd | Helicobacter pylori adhesion-inhibiting composition, and food and drink |
| CN106343022A (en) * | 2016-08-19 | 2017-01-25 | 盛昌达国际贸易（天津）有限公司 | Health-care yoghurt with helicobacter pylori inhibiting effect and production method of health-care yoghurt |
| CN106491657A (en) * | 2016-10-25 | 2017-03-15 | 广西泰和制药有限公司 | A kind of health food for strengthening regulating intestinal canal flora function and preparation method thereof |
| CN106901344A (en) * | 2017-03-16 | 2017-06-30 | 北京知蜂堂健康科技股份有限公司 | A kind of composition for alleviating stomachache stomachache and its application |
| CN107149151A (en) * | 2017-06-05 | 2017-09-12 | 上海真合生物技术有限公司 | The probiotic composition of helicobacter pylori resistant |
| CN107996936A (en) * | 2017-12-15 | 2018-05-08 | 徐州统食品工业有限公司 | A kind of solid beverage for improving stomach health problem |
| CN108904546A (en) * | 2018-07-10 | 2018-11-30 | 山东腾贵医药有限公司 | A kind of pair of helicobacter pylori has inhibition, the probiotic combinations preparation of killing effect and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110638050A (en) * | 2019-10-08 | 2020-01-03 | 大连山海物华科技开发有限公司 | Health food for resisting helicobacter pylori, invigorating spleen and removing dampness and preparation thereof |
| CN111671079A (en) * | 2020-05-13 | 2020-09-18 | 优益生活(北京)健康科技有限公司 | Composite probiotic powder composition and preparation method thereof |
| CN113287754A (en) * | 2021-05-26 | 2021-08-24 | 北京东方红航天生物技术股份有限公司 | Food composition for resisting helicobacter pylori |
| CN114306395A (en) * | 2021-12-29 | 2022-04-12 | 湖南营养树生物科技有限公司 | Probiotic composition capable of releasing ORNs and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109645489A (en) | A kind of probiotic composition and its application for inhibiting helicobactor pylori activity | |
| Lenoir-Wijnkoop et al. | Probiotic and prebiotic influence beyond the intestinal tract | |
| RU2332224C1 (en) | APPLICATION OF THERAPEUTICALLY EFFECTIVE QUANTITY OF Bb-12 AND LGG FOR PRODUCTION OF CURING OR RESPIRATORY INFECTION AND ACUTE MEDIA OTITIS PREVENTING MEDIUM FOR BABIES | |
| Vanderhoof et al. | Use of probiotics in childhood gastrointestinal disorders | |
| Reid | Probiotics and prebiotics–progress and challenges | |
| US10638784B2 (en) | Lactobacillus composition for inhibiting gastritis induced by gastric helicobacter pylori and use thereof | |
| CN107594284A (en) | A kind of solid beverage containing prebiotics and probiotics and preparation method thereof | |
| CN108004189A (en) | A kind of compound probiotic lactic acid bacteria powder and preparation method and application | |
| CN108477617A (en) | A kind of probiotic powder and preparation method thereof to relax bowel | |
| CN111035014A (en) | Probiotic preparation and preparation method thereof | |
| CN102245191A (en) | Compositions and methods for improved oral health | |
| CN106036911A (en) | Probiotics diet composition and functional food for regulating blood glucose level | |
| CN111548972A (en) | Lactobacillus plantarum with helicobacter pylori resistance function and application thereof | |
| US10369184B2 (en) | Composition and use thereof in manufacture of product for improving intestinal function | |
| CN113249280B (en) | Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product | |
| CN112386615A (en) | Application of lactobacillus paracasei JLPF-176 for inhibiting helicobacter pylori infection and product | |
| WO2020118576A1 (en) | Use of lactobacillus plantarum twk10 in preparation of composition for resistance to post-exercise inflammation or for reducing body fat | |
| CN102861108A (en) | Pharmaceutical composition for treating constipation and application thereof | |
| CN116987608A (en) | Probiotic composition and application thereof in preparation of depression-complicated diarrhea-type irritable bowel syndrome medicines | |
| CN105535580A (en) | A biological agent for improving human body intestinal floras and a preparing method thereof | |
| CN113750113B (en) | Composition of probiotics and prebiotics and application thereof | |
| TW202103717A (en) | Lactobacillus fermentum strain v3 and its efficacies of anti-inflammation and cancer prevention | |
| Wei et al. | The postbiotic of hawthorn-probiotic ameliorating constipation caused by loperamide in elderly mice by regulating intestinal microecology | |
| CN115119940A (en) | Application of Lactobacillus acidophilus LA85 and Bifidobacterium lactis BLA80 in inhibiting helicobacter pylori | |
| TWI718394B (en) | Lactic acid bacteria composition for inhibiting gastritis caused by helicobacter pylori in stomach and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: No. 101, Xintian Road, Yuhang Economic and Technological Development Zone, Hangzhou City, Zhejiang Province Applicant after: Hangzhou Minsheng Health Pharmaceutical Co.,Ltd. Address before: No. 101, Xintian Road, Yuhang Economic and Technological Development Zone, Hangzhou City, Zhejiang Province Applicant before: HANGZHOU MINSHENG HEALTH MEDICINE Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 313399 No. 101, Xintian Road, Donghu street, Linping District, Hangzhou City, Zhejiang Province Applicant after: Hangzhou Minsheng Health Pharmaceutical Co.,Ltd. Address before: No. 101, Xintian Road, Yuhang Economic and Technological Development Zone, Hangzhou City, Zhejiang Province Applicant before: Hangzhou Minsheng Health Pharmaceutical Co.,Ltd. |